Controlling systolic blood pressure is difficult in patients with diabetic kidney disease exhibiting moderate‐to‐severe reductions in renal function

References

• Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542–549.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephro-pathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–1462.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
   PubMed Web of Science ®Google Scholar
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet. 1997;349:1857–1863.
   PubMed Web of Science ®Google Scholar
• Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73–87.
   PubMed Web of Science ®Google Scholar
• Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334:939–945.
   Google Scholar
• Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, et al. Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol. 1999;33 Suppl 1:S16–20.
   Google Scholar
• Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised con-trolled trial. Lancet. 2003;361:117–124.
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkannen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321:1440–1444.
   Google Scholar
• Rosner MH, Okusa MD. Combination therapy with angio-tensin-converting enzyme inhibitors and angiotensin receptor antagonists in the treatment of patients with type 2 diabetes mellitus. Arch Intern Med. 2003;163:1025–1029.
   PubMedGoogle Scholar
• Kuriyama S, Tomonari H, Abe A, Imasawa T, Hosoya T. Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy. Nephron. 2000;86: 529–530.
   Google Scholar
• Orth SR, Amann K, Strojek K, Ritz E. Sympathetic overactivity and arterial hypertension in renal failure. Nephrol Dial Transplant. 2001;16 Suppl 1:67–69.
   PubMedGoogle Scholar
• Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortal-ity among patients with end-stage renal disease. Kidney Int. 2002;61:2157–2164.
   Google Scholar
• Tepel M, Giet MV, Park A, Zidek W. Association of calcium channel blockers and mortality in haemodialysis patients. Chin Sci (Lond). 2002;103:511–515.
   PubMed Web of Science ®Google Scholar
• Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs arnlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA. 2001;285:2719–2728.
   PubMed Web of Science ®Google Scholar
• Griffith TF, Chua BS, Allen AS, Klassen PS, Reddan DN, Szczech LA. Characteristics of treated hypertension in incident hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2003;42:1260–1269.
   PubMed Web of Science ®Google Scholar
• Brazy PC, Fitzwilliam JF. Progressive renal disease: Role of race and antihypertensive medications. Kidney hit. 1990;37:1113–1119.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAN1A. 2003;289: 2560–2572.
   Google Scholar
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hyper-tension. J Hypertens. 2003;21: 1011–1053.
   Google Scholar
• Whitworth JA. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003; 21:1983–1992.
   Google Scholar
• K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.
   Google Scholar
• Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641–650.
   Google Scholar
• Tomlinson JW, Owen KR, Close CF. Treating hypertension in diabetic nephropathy. Diabetes Care. 2003;26:1802–1805.
   PubMedGoogle Scholar
• Fagerudd J, Forsblom C, Pettersson-Fernholm K, Groop PH. Implementation of guidelines for the prevention of diabetic nephropathy. Diabetes Care. 2004;27:803–804.
   PubMed Web of Science ®Google Scholar
• Prosch LK, Sxlen MG, Gudmundsdottir H, Dyrbekk D, Hunderi OH, Arnesen E, et al. Blood pressure control is hard to obtain in patients with chronic renal failure. Results from a survey in renal units in Norway. Scand J Urol Nephrol. 2005; in press.
   Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Coresh J, Wei GL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ. Prevalence of high blood pressure and elevated serum creatinine level in the United States: Findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2001; 161:1207–1216.
   Google Scholar
• Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086–1097.
   PubMed Web of Science ®Google Scholar
• Westheim A, Klemetsrud T, Tretli S, Stokke HP, Olsen H. Blood pressure levels in treated hypertensive patients in general practice in Norway. Blood Press. 2001;10:37–42.
   Google Scholar
• Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 2003;64:1772–1779.
   PubMed Web of Science ®Google Scholar
• Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? Am J Hypertens. 1999;12:1955–2035.
   Google Scholar
• Pisoni R, Faraone R, Ruggenent P, Remuzzi G. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency. J Nephrol. 2002;15:428–430.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: When to start and why possibly never to stop. A post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001;12:2832–2837.
   Google Scholar